Melissa M. Winder

Melissa M. Winder

Auto-generated profile, based on publicly available information

Melissa M. Winder

University of Utah

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2022 in Cardiology in the Young
Verified
Journal Article
Closed access
PDF file
RLRichard P. Lion
Richard P. Lion
MWMelissa M. Winder
Melissa M. Winder
RARambod Amirnovin
Rambod Amirnovin
KFKristi Fogg
Kristi Fogg
RBRebecca Bertrandt
Rebecca Bertrandt
DBDavid K. Bailly
David K. Bailly
Objective: A standardised multi-site approach to manage paediatric post-operative chylothorax does not exist and leads to unnecessary practice variation. The Chylothorax Work Group utilised the Pediatric Critical Care Consortium infrastructure to address this gap.Methods: Over 60 multi-disciplinary providers representing 22 centres convened virtually as a quality initiative to develop an algorithm to manage paediatric post-operative chylothorax. Agreement was objectively quantified for each recommendation in the algorithm by utilising an anonymous survey. “Consensus” was defined as ≥ 80% of responses as “agree” or “strongly agree” to a recommendation. In order to determine if the algorithm recommendations would be correctly interpreted in the clinical environment, we developed ex vivo simulations and surveyed patients who developed the algorithm and patients who did not.Results: The algorithm is intended for all children (80%) by the workgroup (range 81–100%). Ex vivo simulations demonstrated good understanding by developers (range 94–100%) and non-developers (73%–100%).Conclusions: The quality improvement effort represents the first multi-site algorithm for the management of paediatric post-operative chylothorax. The algorithm includes transparent and objective measures of agreement and understanding. Agreement to the algorithm recommendations was >80%, and overall understanding was 94%.

25 April 2018 in Cardiology in the Young
Verified
Journal Article
Closed access
PDF file
MWMelissa M. Winder
Melissa M. Winder
AEAaron W. Eckhauser
Aaron W. Eckhauser
CDClaudia Delgado-Corcoran
Claudia Delgado-Corcoran
RSRandall J. Smout
Randall J. Smout
JMJennifer Marietta
Jennifer Marietta
DBDavid K. Bailly
David K. Bailly
Objective: Our primary goal was to decrease time to resolution of postoperative chylothorax as demonstrated by total days of chest tube utilisation through development and implementation of a management protocol.Methods: A chylothorax management protocol was implemented as a quality improvement project at a tertiary-care paediatric hospital in July, 2015. Retrospective analysis was completed on patients aged 0–17 years diagnosed with chylothorax within 30 days of cardiac surgery in a pre-protocol cohort (February, 2014 to June, 2015, n=20) and a post-protocol cohort (July, 2015 to March, 2016, n=22).Measurements and results: Patient characteristics were similar before and after protocol implementation. Duration of mechanical ventilation and cardiac ICU and hospital lengths of stay were unchanged between cohorts. Following protocol implementation, total duration of chest tube utilisation decreased from 12 to 7 days (p=0.047) with a decrease in maximum days of chest tube utilisation from 44 to 13 days. Duration of medium-chain triglyceride feeds decreased from 42 days to 31 days (p=0.01). In total, three patients in the post-protocol cohort underwent additional surgical procedures to treat chylothorax with subsequent resolution of chylothorax within 24 hours. There were no chest tube re-insertions or re-admissions related to chylothorax in either the pre- or post-protocol cohorts. Protocol compliance was 81%.Conclusions: Adoption of a chylothorax management protocol is feasible, and in our small cohort of patients implementation led to a significant decrease in the duration of chest tube utilisation, while eliminating practice variability among providers.

13 February 2021 in Pediatric Cardiology
Verified
Journal Article
Closed access
PDF file
MWMelissa M. Winder
Melissa M. Winder
JMJennifer Marietta
Jennifer Marietta
LKLynne M. Kerr
Lynne M. Kerr
MPMichael D. Puchalski
Michael D. Puchalski
CZChong Zhang
Chong Zhang
CCCollin G. Cowley
Collin G. Cowley

30 September 2022 in Cardiology in the Young
Verified
Journal Article
Open access
PDF file
KFKristi L. Fogg
Kristi L. Fogg
ATAmiee Trauth
Amiee Trauth
MHMegan Horsley
Megan Horsley
PVPiyagarnt Vichayavilas
Piyagarnt Vichayavilas
MWMelissa Winder
Melissa Winder
EGErin E. Gordon
Erin E. Gordon
Introduction: Chylothorax after congenital cardiac surgery is associated with increased risk of malnutrition. Nutritional management following chylothorax diagnosis varies across sites and patient populations, and a standardised approach has not been disseminated. The aim of this review article is to provide contemporary recommendations related to nutritional management of chylothorax to minimise risk of malnutrition.Methods: The management guidelines were developed by consensus across four dietitians, one nurse practitioner, and two physicians with a cumulative 52 years of experience caring for children with CHD. A PubMed database search for relevant literature included the terms chylothorax, paediatric, postoperative, CHD, chylothorax management, growth failure, and malnutrition.Results: Fat-modified diets and nil per os therapies for all paediatric patients (<18 years of age) following cardiac surgery are highlighted in this review. Specific emphasis on strategies for treatment, duration of therapies, optimisation of nutrition including nutrition-focused lab monitoring, and supplementation strategies are provided.Conclusions: Our deliverable is a clinically useful guide for the nutritional management of chylothorax following paediatric cardiac surgery.

18 November 2021 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
PDF file
MWMelissa M. Winder
Melissa M. Winder
SVSenthuran Vijayarajah
Senthuran Vijayarajah
RRRon W. Reeder
Ron W. Reeder
EGEmilee T. Glenn
Emilee T. Glenn
RMRohin Moza
Rohin Moza
DBDavid K. Bailly
David K. Bailly

29 August 2020 in Perfusion
Verified
Journal Article
Closed access
PDF file
DBDavid K. Bailly
David K. Bailly
JFJamie M Furlong-Dillard
Jamie M Furlong-Dillard
MWMelissa Winder
Melissa Winder
MLMark Lavering
Mark Lavering
RBRyan P Barbaro
Ryan P Barbaro
RRRon W Reeder
Ron W Reeder
Introduction: The Pediatric Extracorporeal Membrane Oxygenation Prediction (PEP) model was created to provide risk stratification for all pediatric patients requiring extracorporeal life support (ECLS). Our purpose was to externally validate the model using contemporaneous cases submitted to the Extracorporeal Life Support Organization (ELSO) registry. Methods: This multicenter, retrospective analysis included pediatric patients (<19 years) during their initial ECLS run for all indications between January 2012 and September 2014. Median values from the BATE dataset for activated partial thromboplastin time and internationalized normalized ratio were used as surrogates as these were missing in the ELSO group. Model discrimination was evaluated using area under the receiver operating characteristic curve (AUC), and goodness-of-fit was evaluated using the Hosmer-Lemeshow test. Results: A total of 4,342 patients in the ELSO registry were compared to 514 subjects from the bleeding and thrombosis on extracorporeal membrane oxygenation (BATE) dataset used to develop the PEP model. Overall mortality was similar (42% ELSO vs. 45% BATE). The c-statistic after external validation decreased from 0.75 to 0.64 and model calibration decreases most in the highest risk deciles. Conclusion: Discrimination of the PEP model remains modest after external validation using the largest pediatric ECLS cohort. While the model overestimates mortality for the highest risk patients, it remains the only prediction model applicable to both neonates and pediatric patients who require ECLS for any indication and thus maintains potential for application in research and quality benchmarking.